Statement: The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.
Primary_evidence: Outcome Measurement:    Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])   The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method.   Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks) Results 1:    Arm/Group Title: Ixabepilone 40 mg/m^2   Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks   Overall Number of Participants Analyzed: 40   Measure Type: Number   Unit of Measure: percentage of participants  30.0        (16.6 to 46.5) Results 2:    Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2   Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks   Overall Number of Participants Analyzed: 39   Measure Type: Number   Unit of Measure: percentage of participants  35.9        (21.2 to 52.8)